In a murine xenograft experiment using KRAS-mutant PDCLs (Pa01c and Pa02c), the triplet of ulixertinib, gemcitabine and paclitaxel was more effective in suppressing, but did not regress, tumour growth (Fig. 1d). The gene discussed is KRAS; the disease is neoplasm.